Prevalence and Risk Factors of Post-COVID-19 Condition in Adults and Children at 6 and 12 Months After Hospital Discharge: A Prospective, Cohort Study in Moscow (Stop COVID)

Pazukhina, Ekaterina; Andreeva, Margarita; Spiridonova, Ekaterina; Bobkova, Polina; Shikhaleva, Anastasia; El‐Taravi, Yasmin; Rumyantsev, Mikhail; Gamirova, Aysylu; Bairashevskaia, Anastasiia; Petrova, Polina; Baimukhambetova, Dina; Pikuza, Maria; Abdeeva, Elina; Filippova, Yulia; Deunezhewa, Salima; Nekliudov, Nikita A; Bugaeva, Polina; Bulanov, Nikolay; Авдеев, С. Н.; Капустина, Валентина; Guekht, Alla; DunnGalvin, Audrey; Comberiati, Pasquale; Peroni, Diego; Apfelbacher, Christian; Genuneit, Jon; Reyes, Luis Felipe; Brackel, Caroline L H; Fоmin, Victоr; Svistunov, Andrey; Timashev, Peter; Mazankova, Lyudmila; Miroshina, Alexandra; Самитова, Э. Р.; Борзакова, С. Н.; Bondarenko, Elena; Korsunskiy, Anatoliy A.; Carson, Gail; Sigfrid, Louise; Scott, Janet T.; Greenhawt, Matthew; Buonsenso, Danilo; Semple, Malcolm; Warner, John O.; Olliaro, Piero; Глыбочко, П. В.; Butnaru, Denis; Османов, И. М.; Munblit, Daniel

doi:10.2139/ssrn.4020142

Cited by 34 publications

(37 citation statements)

References 21 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is further substantiated by the findings in a study that, Persistent symptoms were highly prevalent, especially fatigue, shortness of breath, headache, brain fog/confusion, and altered taste/smell, which persisted beyond 1 year (12 months) among 56% 83 . Contrary to the current findings though, some studies have reported a decreasing post-acute COVID-19 sequalae from sixth to twelfth month 1,82…”

Section: Discussioncontrasting

confidence: 99%

“…A forty-five per cent (45%) of health care workers also reported persistent symptoms at three to four months 81 . As regards post COVID-19 sequalae at six months (6-months), a previous study shows post-acute COVID-19 sequalae prevalence was 50% in adults at 6 months 82 , close to the 54% in the current findings. At 12 months, post-acute COVID-19 sequalae was reported as (50%) ≥1 PASC symptom, close to 58% as per the current findings.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Event Rate and Predictors of Post-Acute COVID-19 Sequalae and the Average Time to Diagnosis in General Population

Muthuka

Mativo

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Post-COVID-19 sequalae involves a variety of new, returning or ongoing symptoms that people experience more than four weeks after getting COVID-19. The aims of this meta-analysis were to assess the prevalence of Post-Acute COVID-19 sequalae and estimate the average time to its diagnosis; and meta-regress for possible moderators. Methods: A standard search strategy was used in PubMed, and then later modified according to each specific database. Search terms included; long COVID-19 or post-acute COVID-19 syndrome/sequalae. The criteria for inclusion were published clinical articles reporting the long COVID-19, further, the average time to diagnosis of post-acute COVID-19 sequelae among primary infected patients with COVID-19. Random-effects model was used. Rank Correlation and Eggers tests were used to ascertain publication bias. Sub-group, sensitivity and meta-regression analysis were conducted. A 95% confidence intervals were presented and a p-value < 0.05 was considered statistically significant. Review Manager 5.4 and comprehensive meta-analysis version 4 (CMA V4) were used for the analysis. The trial was PROSPERO registered (CRD42022328509). Results: Prevalence of post-acute COVID-19 sequalae was 42.5% (95% confidence interval (CI) 36 % to 49.3%). The PACS event rates range was 25 % at four months and 66 % at two months and mostly, signs and symptoms of PASC were experienced at three (54.3%, P < 0.0001) to six months (57%, P < 0.0001), further increasing at 12 months (57.9%, P= 0.0148). At an average of two months, however with the highest event rate (66%), it was not significantly associated with PACS diagnosis (P=0.08). On meta-regression, comorbidities collectively contributed to 14% of PACS with a non-significant correlation (Q = 7.05, df = 8, p = 0.5313) (R-squared analog = 0.14). A cardiovascular disorder especially hypertension as a stand-alone, showed an event rate of 32% and significantly associated with PACS, 0.322 (95% CI 0.166, 0.532) (P < 0.001). Chronic obstructive pulmonary disorder (COPD) and abnormal basal metabolic index (BMI) had higher event rates of PACS (59.8 % and 55.9 %) respectively, with a non-significant correlation (P > 0.05). With a significant association, hospital re-admission contributed to 17% (Q = 8.70, df = 1, p = 0.0032) (R-squared analog= 0.17) and the study design 26% (Q = 14.32, df = 3, p = 0.0025) (R-squared analog= 0.26). All the covariates explained at least some of the variance in effect size on PACS at 53% (Q = 38.81, df = 19, p = 0.0047) (R-squared analog = 0.53). Conclusion: The prevalence of PACS in general population was 42.5%, of which cardiovascular disorders were highly linked with it with COPD and abnormal BMI also being possible conditions found in patients with PACS. Hospital re-admission predicted highly, an experience of PACS as well as prospective study design. Clinical and methodological characteristics in a specific study contributed to over 50% of PACS events. The PACS event rates ranged between 25 % at four months and 66 % at two months with most signs and symptoms experienced between three to six months increasing at 12 months.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 85%

Event Rate and Predictors of Post-Acute COVID-19 Sequalae and the Average Time to Diagnosis in General Population

Muthuka

Mativo

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The literature is mixed on the risk factors for long-COVID. A prospective cohort study in revealed that females and patients with comorbidities were at higher risk of developing long-COVID symptoms 17 , consistent with our findings although comorbidities were not significant at the multivariate level. A Jordan study found that female patients, older patients, and patients with comorbidities had a significantly increased risk of developing long-COVID 37 .…”

Section: Discussionsupporting

confidence: 90%

“…Many theories have been proposed to explain its etiology, such as persistent reservoirs of SARS-CoV-2 in tissues, immunological dysregulation, autoimmunity, clotting and endothelial abnormalities, and dysfunctional signaling in the nervous system 8 , 16 . The risk factors that increase the occurrence of long COVID include older age, female gender, type 2 diabetes, certain autoantibodies, hospitalization, and certain socioeconomic conditions such as a lower income 17 – 19 .…”

Section: Introductionmentioning

confidence: 99%

A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination

Hamdh

Nazzal

2023

Sci Rep

View full text Add to dashboard Cite

Current studies about the long-term effects of COVID-19 show a wide range of symptoms. This prospective cohort study aimed to find the incidence of long-COVID symptoms and the associated risk factors. We followed 669 confirmed COVID-19 patients. Sociodemographic and clinical data were extracted from medical records and collected via semi-structured telephone interviews on days 10, 30, 60, and 90. The incidence of long-COVID symptoms was 41.6% (95% CI 37.8–45.4%). Females [aOR = 1.5 (95% CI 1.1–2.3)], the elderly [aOR = 4.9 (95% CI 2.0–11.3)], and those who required hospitalization [aOR = 5.0 (95% CI 1.3–3.7)] were at a higher risk of developing long-COVID. Patients with dyspnea at day 10 [aOR: 2.4 (95% CI 1.6–3.7] and fatigue at day 60 [aOR: 3.1 (95% CI 1.5–6.3] were also at risk. While non-vaccinated patients were almost seven times more likely to report long-COVID symptoms than vaccinated patients [aOR: 6.9 (95% CI 4.2–11.3)]. In conclusion, long-COVID was common among COVID-19 patients, with higher rates among females, older age groups, hospitalized patients, and those with dyspnea and fatigue, while vaccination provided protection. Interventions should educate health professionals, raise general public awareness about the risks and consequences of Long COVID, and the value of vaccination.

show abstract

“…The literature on the risk factors of long-COVID symptoms is still inconsistent. A prospective cohort study in Moscow found that females were twice as likely as males to have long-COVID symptoms and that having comorbidities was signi cantly associated with developing long-COVID symptoms 30 . Another study in Jordan found that female patients, older patients, and patients with comorbidities had a signi cantly increased risk of developing long-COVID symptoms 28 .…”

Section: Discussionmentioning

confidence: 99%

Long-COVID symptom risk among COVID-19 patients and its relationship to COVID-19 vaccination; a prospective cohort study

Hamdah

Nazzal

2022

Preprint

View full text Add to dashboard Cite

The acute COVID-19 presentation is well described in the literature, but the long-term effect is unclear. This study aims to find the incidence of long-COVID symptoms and the associated risk factors among COVID-19 patients. A prospective cohort study in Palestine included 669 confirmed COVID-19 patients. Sociodemographic and clinical data were extracted from their medical records and collected via semi-structured telephone interviews on Days 10, 30, 60, and 90 using a semi-structured questionnaire. The incidence of long-COVID symptoms was 41.6% (95%CI: 37.8–45.4%). Females [aOR = 1.5 (95%CI:1.1–2.3)], the elderly [aOR = 4.9 (95%CI:2.0-11.3)], and those who required hospitalization [aOR = 5.0 (95%CI:1.3–3.7)] were at a higher risk of developing long-COVID symptoms, as well as patients with dyspnea at day ten [aOR:2.4 (95%CI: 1.6–3.7] and fatigue at day 60 [aOR:3.1 (95%CI:1.5–6.3]. On the other hand, vaccination was found to be protective; non-vaccinated patients were almost seven times more likely than vaccinated patients to report long symptoms [aOR:6.9 (95%CI:4.2–11.3)]. In conclusion, long-COVID symptoms are common among COVID-19 patients, with higher rates among females, older age groups, hospitalized patients, and those with dyspnea and fatigue, while vaccination has proven effective. Therefore, it is essential to identify at-risk patients early and provide appropriate management.

show abstract

Prevalence and Risk Factors of Post-COVID-19 Condition in Adults and Children at 6 and 12 Months After Hospital Discharge: A Prospective, Cohort Study in Moscow (Stop COVID)

Cited by 34 publications

References 21 publications

Event Rate and Predictors of Post-Acute COVID-19 Sequalae and the Average Time to Diagnosis in General Population

Event Rate and Predictors of Post-Acute COVID-19 Sequalae and the Average Time to Diagnosis in General Population

A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination

Long-COVID symptom risk among COVID-19 patients and its relationship to COVID-19 vaccination; a prospective cohort study

Contact Info

Product

Resources

About